ARTICLE | Clinical News
Yondelis trabectedin: Phase II data
June 22, 2009 7:00 AM UTC
PharmaMar S.A., Madrid, Spain Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: Yondelis trabectedin ( ET-743) Business: Cancer Molecular target: DNA Description: Cytotoxic alkaloid that bi...